ERBB2 and gastroesophageal junction adenocarcinoma: The non-interventional HERMES trial [69] followed the course of HER2-positive metastatic esophagogastric adenocarcinomas, under therapy with HER2-addressed trastuzumab-containing regimens, according to physicians’ choice.